CA3147082A1 - (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives - Google Patents

(hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives Download PDF

Info

Publication number
CA3147082A1
CA3147082A1 CA3147082A CA3147082A CA3147082A1 CA 3147082 A1 CA3147082 A1 CA 3147082A1 CA 3147082 A CA3147082 A CA 3147082A CA 3147082 A CA3147082 A CA 3147082A CA 3147082 A1 CA3147082 A1 CA 3147082A1
Authority
CA
Canada
Prior art keywords
pyran
triazol
hydroxymethyl
thio
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147082A
Other languages
English (en)
French (fr)
Inventor
Martin Bolli
Daniel Bur
John Gatfield
Corinna Grisostomi
Lubos Remen
Cornelia Zumbrunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3147082A1 publication Critical patent/CA3147082A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3147082A 2019-08-09 2020-08-07 (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives Pending CA3147082A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/071416 2019-08-09
EP2019071416 2019-08-09
PCT/EP2020/072238 WO2021028336A1 (en) 2019-08-09 2020-08-07 (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives

Publications (1)

Publication Number Publication Date
CA3147082A1 true CA3147082A1 (en) 2021-02-18

Family

ID=71948599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147082A Pending CA3147082A1 (en) 2019-08-09 2020-08-07 (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives

Country Status (9)

Country Link
US (1) US12404295B2 (https=)
EP (1) EP4010076B1 (https=)
JP (1) JP7612662B2 (https=)
KR (1) KR102854071B1 (https=)
CN (1) CN114206893A (https=)
CA (1) CA3147082A1 (https=)
ES (1) ES2972509T3 (https=)
TW (1) TWI873165B (https=)
WO (1) WO2021028336A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
WO2022189459A2 (en) * 2021-03-10 2022-09-15 Galecto Biotech Ab Novel galactoside inhibitor of galectins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP6904906B2 (ja) 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
KR101974793B1 (ko) 2015-07-06 2019-05-02 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
JP7086008B2 (ja) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用
CA3025867A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US20200061095A1 (en) 2017-05-12 2020-02-27 Galectin Sciences, Llc Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
AU2018361991A1 (en) 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
JP2022508719A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤のプロドラッグ
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
JP7486484B2 (ja) 2018-11-21 2024-05-17 ガレクト バイオテック エービー ガレクチンのα－Ｄ－ガラクトシド阻害剤
EP3953349A1 (en) 2019-04-10 2022-02-16 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CA3141436A1 (en) 2019-07-03 2021-01-07 Fredrik Zetterberg Novel galactoside inhibitor of galectins
CN114450282A (zh) 2019-07-05 2022-05-06 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu

Also Published As

Publication number Publication date
US20220315619A1 (en) 2022-10-06
TWI873165B (zh) 2025-02-21
KR102854071B1 (ko) 2025-09-02
EP4010076B1 (en) 2024-01-17
JP2022543666A (ja) 2022-10-13
EP4010076C0 (en) 2024-01-17
US12404295B2 (en) 2025-09-02
JP7612662B2 (ja) 2025-01-14
WO2021028336A1 (en) 2021-02-18
KR20220044785A (ko) 2022-04-11
TW202120102A (zh) 2021-06-01
ES2972509T3 (es) 2024-06-13
EP4010076A1 (en) 2022-06-15
CN114206893A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
CA3147082A1 (en) (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
US12410208B2 (en) (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
CA3147454A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
US12291520B2 (en) Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
EP4225752B1 (en) Spiro derivatives of alpha-d-galactopyranosides
CA3209917A1 (en) Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
CA3207214A1 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные
HK40071801A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
HK40071801B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240729

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240806

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250314

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250314

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250314

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250730

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250908

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260106